Literature DB >> 12706410

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.

Petra Lenz1, Cynthia D Thompson, Patricia M Day, Silvia M Bacot, Douglas R Lowy, John T Schiller.   

Abstract

Papillomavirus-like particles (VLPs) are potent inducers of humoral and cellular immune responses, making them attractive candidates for noninfectious viral subunit vaccines. To further our understanding of how VLPs activate the immune system, we have investigated their interaction with human myeloid antigen-presenting cells. We found that VLPs bound, with increasing density, to the cell surface of human monocytes, macrophages, and monocyte-derived dendritic cells (DCs). Interestingly, there was a negative correlation between binding intensity and CD83 expression in DCs, suggesting that the main receptor for binding of VLPs may be downregulated during maturation. Exposure to VLPs resulted in acute phenotypic activation of monocytes and DCs. Furthermore, VLPs rapidly induced production of inflammatory cytokines in monocytes, macrophages, and DCs, as assessed by intracellular cytokine staining. For each cell type, the patterns of interleukin-1beta, interleukin-12, tumor necrosis factor-alpha, and interleukin-6 production were distinct from the pattern induced by lipopolysaccharide (LPS), a bacterial activator of myeloid antigen-presenting cells. Our results indicate that VLPs target multiple cells of the immune system, which helps to account for VLPs being so effective in priming humoral and cellular immune responses even in the absence of adjuvant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706410     DOI: 10.1016/s1521-6616(02)00039-6

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  30 in total

1.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  Human papillomavirus capsids preferentially bind and infect tumor cells.

Authors:  Rhonda C Kines; Rebecca J Cerio; Jeffrey N Roberts; Cynthia D Thompson; Elisabet de Los Pinos; Douglas R Lowy; John T Schiller
Journal:  Int J Cancer       Date:  2015-10-27       Impact factor: 7.396

Review 3.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

4.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

6.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

Review 7.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

8.  Murine polyomavirus-like particles induce maturation of bone marrow-derived dendritic cells and proliferation of T cells.

Authors:  Thomas Bickert; Gisela Wohlleben; Marc Brinkman; Claudia M Trujillo-Vargas; Claus Ruehland; Christian O A Reiser; Juergen Hess; Klaus J Erb
Journal:  Med Microbiol Immunol       Date:  2006-08-18       Impact factor: 3.402

9.  Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Catherine Hervouet; Hye-Ran Cha; Yuk-Ying S Pang; Jan Holmgren; Konrad Stadler; John T Schiller; Fabienne Anjuère; Cecil Czerkinsky
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 10.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.